Cytek Biosciences Inc (NAS:CTKB)
$ 3.4 -0.36 (-9.57%) Market Cap: 430.64 Mil Enterprise Value: 226.52 Mil PE Ratio: 0 PB Ratio: 1.14 GF Score: 70/100
Back to the Transcripts List

Q1 2025 Cytek Biosciences Inc Earnings Call Transcript

May 8, 2025 / 08:30 PM GMT
Release Date Price: $3.79 (+1.61%)

Key Points

Positve
  • Service revenue worldwide increased by 24% year-over-year, driven by the expansion of the instrument installed base and active usage across various disciplines.
  • Cytek Biosciences Inc (CTKB) experienced strong demand in the Asia Pacific and other international markets, with revenue in these regions growing by 35.6% year-over-year.
  • The company launched a new microcell analyzer, expanding its capabilities and targeting emerging markets such as cell and gene therapy.
  • Recurring revenue, including reagents and service revenue, grew to represent 31% of total revenue, up from 26% a year ago.
  • Cytek Biosciences Inc (CTKB) maintains a strong balance sheet, allowing for continued investment in growth and innovation.
Negative
  • First quarter revenue decreased by 7.6% compared to the first quarter of 2024, primarily due to weakness in instrument sales in the US and Europe.
  • Product revenue, including instruments and reagents, decreased by 18% year-over-year, impacted by academic funding uncertainties and cautious capital spending in the biotech and pharma industries.
  • Gross profit decreased by 12% compared to the previous year, with a decline in both GAAP and non-GAAP gross margins.
  • The company revised its full-year 2025 revenue outlook downward due to significant changes in the market environment, including uncertainties in academic funding and government budgets.
  • Operating expenses increased, leading to a larger loss from operations compared to the prior year quarter.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CTKB.OQ - Cytek Biosciences Inc
Q1 2025 Cytek Biosciences Inc Earnings Call
May 08, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you for standing by. At this time, I would like to welcome everyone to the Scitech Biosciences first quarter 2025 earnings conference call. All lines have been placed on you to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star, followed by the number one on your telephone keypad. If you would like to withdraw your question, press one again.

I would not like to turn the conference over to Paul Goodson, head of investor relations. Please go ahead, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
---------------------------
Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2025 GuruFocus.com, LLC. All Rights Reserved.